Access Archived VideoConferences
Passcode: 47532
The corresponding reading articles are found below.
Fellows National Video Conference 2020
Genomic Profiling of Small-Bowel Adenocarcinoma
Alexa B. Schrock, PhD; Craig E. Devoe, MD; Robert McWilliams, MD; James Sun, PhD;
Thomas Aparicio, MD; Philip J. Stephens, PhD; Jeffrey S. Ross, MD; Richard Wilson, MD;
Vincent A. Miller, MD; Siraj M. Ali, MD, PhD; Michael J. Overman, MD
Efficacy of Adjuvant Chemotherapy for Small Bowel
Adenocarcinoma: A Propensity Score–Matched Analysis
Brett L. Ecker, MD; Matthew T. McMillan, BA; Jashodeep Datta, MD; Ronac Mamtani, MD, MSCE; Bruce J. Giantonio, MD;
Daniel T. Dempsey, MD; Douglas L. Fraker, MD; Jeffrey A. Drebin, MD, PhD1; Giorgos C. Karakousis, MD; and
Robert E. Roses, MD
Resection of small bowel adenocarcinoma metastases: Results of the
ARCAD-NADEGE cohort study
Pierre Rompteaux, Johan Gagnière, Jean-Marc Gornet, Romain Coriat,
Isabelle Baumgaertner, Thierry Lecomte, Pauline Afchain, Aziz Zaanan,
Marc Pocard, Jean-Baptiste Bachet, Nathalie Bonichon-Lamichhane, Olivier Bouché,
Jean-Luc Faucheron, Julien Forestier, Cedric Lecaille, Sylvain Manfredi,
David Tougeron, Eric Terrebonne, Mohamad Chehimi, Anne-Laure Villing,
Corinne Sarda, Jean-Louis Legoux, Robert Benamouzig, Thomas Aparicio
Phase III Trial to Compare Adjuvant Chemotherapy With
Capecitabine and Cisplatin Versus Concurrent
Chemoradiotherapy in Gastric Cancer: Final Report of the
Adjuvant Chemoradiotherapy in Stomach Tumors Trial,
Including Survival and Subset Analyses
Se Hoon Park, Tae Sung Sohn, Jeeyun Lee, Do Hoon Lim, Min Eui Hong, Kyoung-Mee Kim, Insuk Sohn,
Sin Ho Jung, Min Gew Choi, Jun Ho Lee, Jae Moon Bae
Perioperative chemotherapy with fluorouracil plus
leucovorin, oxaliplatin, and docetaxel versus fluorouracil or
capecitabine plus cisplatin and epirubicin for locally
advanced, resectable gastric or gastro-oesophageal junction
adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Thorsten O Goetze, Johannes Meiler, Stefan Kasper, Hans-Georg Kopp, Frank Mayer,
Georg Martin Haag, Kim Luley , Udo Lindig, Wolff Schmiegel, Michael Pohl, Jan Stoehlmacher, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar,
Wolfgang Fischbach, Rolf Mahlberg, Jörg Trojan, Michael Koenigsmann, Uwe M Martens, Peter Thuss-Patience, Matthias Egger, Andreas Block,
Volker Heinemann, Gerald Illerhaus, Markus Moehler, Michael Schenk, Frank Kullmann, Dirk M Behringer, Michael Heike, Daniel Pink,
Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T Hartmann,
Michael Kneba, Severin Daum, Karsten Schulmann, Jörg Weniger, Sebastian Belle, Timo Gaiser, Fuat S Oduncu, Martina Güntner, Wael Hozaeel,
Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O Bechstein, Martin Schuler, Harald Schmalenberg*, Ralf D Hofheinz*,
on behalf of the FLOT4-AIO Investigators†
Comparison of Surgery Plus Chemotherapy and
Palliative Chemotherapy Alone for Advanced Gastric Cancer with
Krukenberg Tumor
Jang Ho Cho, MD, Jae Yun Lim, MD, PhD, Ah Ran Choi, MD, Sung Min Choi, MD, Jong Won Kim, MD, Seung Ho Choi, MD, PhD, Jae Yong Cho, MD, PhD
Utility of the Proximal Margin Frozen Section for Resection of
Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric
Cancer Collaborative
Malcolm H. Squires III, MD, MS, David A. Kooby, MD, Timothy M. Pawlik, MD, MPH, PhD, Sharon M. Weber,
MD, George Poultsides, MD, Carl Schmidt, MD, Konstantinos Votanopoulos, MD, Ryan C. Fields, MD,
Aslam Ejaz, MD, Alexandra W. Acher, BS, David J. Worhunsky, MD, Neil Saunders, MD, Linda X. Jin, MD,
Edward Levine, MD, Clifford S. Cho, MD, Mark Bloomston, MD, Emily Winslow, MD, Kenneth Cardona, MD,
Charles A. Staley III, MD1, and Shishir K. Maithel, MD
Population-Based Study on Risk Factors for Tumor-Positive
Resection Margins in Patients with Gastric Cancer
Leonie R. van der Werf, MD , Charlotte Cords, MD, Ivo Arntz, MD, PhD, Eric J. T. Belt, MD, PhD,
Ivan M. Cherepanin, MD, PhD, Peter-Paul L. O. Coene, MD, PhD, Erwin van der Harst, MD, PhD,
Joos Heisterkamp, MD, PhD, Barbara S. Langenhoff, MD, PhD, Bas Lamme, MD, PhD,
Mark I. van Berge Henegouwen, MD, PhD, Sjoerd M. Lagarde, MD, PhD, and Bas P. L. Wijnhoven, MD, PhD
Does Adjuvant Chemoradiotherapy Improve the Prognosis
of Gastric Cancer After an R1 Resection? Results from a Dutch
Cohort Study
Jurriën Stiekema, MD, Anouk K. Trip, MD, Edwin P. M. Jansen, MD, PhD, Mieke J. Aarts, PhD,
Henk Boot, MD, PhD, Annemieke Cats, MD, PhD, Olga Balague Ponz, MD, PhD, Patrycja L. Gradowska, PhD,
Marcel Verheij, MD, PhD, and Johanna W. van Sandick, MD, PhD
Fellows National Video Conference 2019
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer,Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Sanjiv S. Agarwala, Mohammed Milhem, Lee Cranmer, Brendan Curti, Karl Lewis, Merrick Ross, Troy Guthrie, Gerald P. Linette, Gregory A. Daniels, Kevin Harrington, Mark R. Middleton, Wilson H. Miller Jr, Jonathan S. Zager, Yining Ye, Bin Yao, Ai Li, Susan Doleman, Ari VanderWalde, Jennifer Gansert, and Robert S. Coffin
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Jason Chesney, Igor Puzanov, Frances Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore F. Logan, Axel Hauschild, Celeste Lebb´e, Lisa Chen, Jenny J. Kim, Jennifer Gansert, Robert H.I. Andtbacka, and Howard L. Kaufman
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
Antoni Ribas, Reinhard Dummer, Igor Puzanov, …, Jennifer Gansert, F. Stephen Hodi, Georgina V. Long
Recurrence After Complete Resection and Selective Use of Adjuvant Therapy for Stage I Through III Merkel Cell Carcinoma
Ryan C. Fields, MD1; Klaus J. Busam, MD2; Joanne F. Chou, MPH3; Katherine S. Panageas, DrPH3; Melissa P. Pulitzer, MD2; Peter J. Allen, MD1; Dennis H. Kraus, MD1; Mary S. Brady, MD1; and Daniel G. Coit, MD
Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base
Shailender Bhatia, Barry E. Storer, Jayasri G. Iyer, Ata Moshiri, Upendra Parvathaneni, David Byrd, Arthur J. Sober, Vernon K. Sondak, Jeffrey E. Gershenwald, Paul Nghiem
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Prof. Howard L Kaufman, MD, Jeffery Russell, MD, Omid Hamid, MD, Shailender Bhatia, MD, Patrick Terheyden, MD, Sandra P D’Angelo, MD, Kent C Shih, MD, Prof. Céleste Lebbé, MD, Gerald P Linette, MD, Michele Milella, MD, Isaac Brownell, MD, Karl D Lewis, MD, Jochen H Lorch, MD, Kevin Chin, MD, Lisa Mahnke, MD, Anja von Heydebreck, PhD, Jean-Marie Cuillerot, MD, and Prof. Paul Nghiem, MD
Management of metastatic retroperitoneal sarcoma: a consensus approach from the Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)
Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG)
Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in areal-life setting: the METASARC observational study
Marion Savina1,2, Axel Le Cesne3, Jean-Yves Blay4, Isabelle Ray-Coquard4, Olivier Mir3, Maud Toulmonde5, Sophie Cousin5, Philippe Terrier6, Dominique Ranchere-Vince7, Pierre Meeus8, Eberhard Stoeckle9, Charles Honoré10, Paul Sargos11, Marie-Pierre Sunyach12, Cécile Le Péchoux13, Antoine Giraud1, Carine Bellera1,2, François Le Loarer14 and Antoine Italiano
Liver resection for metastatic soft tissue sarcoma: An analysis of prognostic factors
R. Marudanayagam *, B. Sandhu, M.T.P.R. Perera, S.R. Bramhall, D. Mayer, J.A.C. Buckels, D.F. Mirza
Surgery to Cure the Zollinger-Ellison Syndrome
Jeffrey A. Norton, M.D., Douglas L. Fraker, M.D., H. Richard Alexander, M.D., David J. Venzon, Ph.D., John L. Doppman, M.D., Jose Serrano, M.D., Ph.D., Stephan U. Goebel, M.D., Paolo L. Peghini, M.D., Praveen K. Roy, M.D., Fathia Gibril, M.D., And Robert T. Jensen, M.D
Surgery Increases Survival in Patients With Gastrinoma
Jeffrey A. Norton, MD, Douglas L. Fraker, MD, H. R. Alexander, MD, Fathia Gibril, MD, David J. Liewehr, MS, David J. Venzon, PhD, and Robert T. Jensen, MD
Prospective Study of the Natural History of Gastrinoma in Patients with MEN1: Definition of an Aggressive and a Nonaggressive Form
Fathia Gibril, David J. Venzon, Jeremiah V. Ojeaburu, Showkat Bashir, and Robert T. Jensen
Arterial resection at the time of pancreatectomy for cancer
Kathleen K. Christians, MD, Charles H. C. Pilgrim, MD, PhD, Susan Tsai, MD, MS,
Paul Ritch, MD, Ben George, MD, Beth Erickson, MD, Parag Tolat, MD, and
Douglas B. Evans, MD
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy, P. Hammel, M. Hebbar, M. Ben Abdelghani, A.C. Wei, J.-L. Raoul, L. Choné, E. Francois, P. Artru, J.J. Biagi, T. Lecomte, E. Assenat, R. Faroux, M. Ychou, J. Volet, A. Sauvanet, G. Breysacher, F. Di Fiore, C. Cripps, P. Kavan, P. Texereau, K. Bouhier-Leporrier, F. Khemissa-Akouz, J.-L. Legoux, B. Juzyna, S. Gourgou, C.J. O’Callaghan, C. Jouffroy-Zeller, P. Rat, D. Malka, F. Castan, and J.-B. Bachet
Radical Surgery of Oligometastatic Pancreatic Cancer
T. Hackert, W. Niesen, U. Hinz, C. Tjaden, O. Strobel, A. Ulrich, C.W. Michalski, M.W. Büchler
Meta-analysis Comparing Upfront Surgery with Neoadjuvant Treatment in Patients with Resectable or Borderline Resectable Pancreatic Cancer
E. Versteijne, J. A. Vogel, M. G. Besselink, O. R. C. Busch2, J. W. Wilmink3, J. G. Daams, C. H. J. van Eijck, B. Groot Koerkamp , C. R. N. Rasch and G. van Tienhoven
Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated with Prolonged Survival in Patients with Pancreatic Cancer?
Jin He, MD PhD, Alex B. Blair, MD, Vincent P. Groot, MD, Ammar A. Javed, MD, Richard A. Burkhart, MD, Georgios Gemenetzis, MD, Ralph H. Hruban, MD, Kevin M. Waters, MD, PhD, Justin Poling, MD, Lei Zheng, MD, PhD, Daniel Laheru, MD, Joseph M. Herman, MD, MSc, Martin A. Makary, MD, MPH, Matthew J. Weiss, MD, John L. Cameron, MD, and Christopher L. Wolfgang, MD, PhD
Total Neoadjuvant Therapy with FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
Janet E. Murphy, MD, MPH; Jennifer Y.Wo, MD; David P. Ryan, MD;Wenqing Jiang, MS; Beow Y. Yeap, ScD; Lorraine C. Drapek, NP, PhD; Lawrence S. Blaszkowsky, MD; Eunice L. Kwak, MD, PhD; Jill N. Allen, MD; JeffreyW. Clark, MD; Jason E. Faris, MD;
Andrew X. Zhu, MD, PhD; Lipika Goyal, MD, MPhil; Keith D. Lillemoe, MD; Thomas F. DeLaney, MD; Carlos Fernández-del Castillo, MD; Cristina R. Ferrone, MD; Theodore S. Hong, MD
Improving Selection for Resection of Synchronous Para-Aortic Lymph Node Metastases in Colorectal Cancer
Kazunosuke Yamada, Shunsuke Tsukamoto, Hiroki Ochiai, Dai Shida, Yukihide Kanemitsu
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
Andrea Cercek, MD; Campbell S.D. Roxburgh, MD, PhD; Paul Strombom, MD; J. Joshua Smith, MD, PhD; Larissa K.F. Temple, MD; Garrett M. Nash, MD; Jose G. Guillem, MD; Philip B. Paty, MD; Rona Yaeger, MD; Zsofia K. Stadler, MD; Kenneth Seier, MS; Mithat Gonen, PhD; Neil H. Segal, MD, PhD; Diane L. Reidy, MD; Anna Varghese, MD; Jinru Shia, MD; Efsevia Vakiani, MD, PhD; Abraham J.Wu, MD; Christopher H. Crane, MD; Marc J. Gollub, MD; Julio Garcia-Aguilar,MD, PhD; Leonard B. Saltz, MD; Martin R. Weiser,MD
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
Julio Garcia-Aguilar, Oliver S Chow, David D Smith, Jorge E Marcet, Peter A Cataldo, Madhulika G Varma, Anjali S Kumar, Samuel Oommen, Theodore Coutsoftides, Steven R Hunt, Michael J Stamos, Charles A Ternent, Daniel O Herzig, Alessandro Fichera, Blase N Polite, David W Dietz, Sujata Patil, Karin Avila, for the Timing of Rectal Cancer Response to Chemoradiation Consortium
Quality of Life After Surgery for Colon Cancer in Patients With Lynch Syndrome: Partial Versus Subtotal Colectomy
Jasmijn F. Haanstra, M.D., Wouter H. de Vos tot Nederveen Cappel, M.D., Ph.D. Jessica P. Gopie, M.Sc., Juda Vecht, M.D., Ph.D., Steven A. L. W. Vanhoutvin, M.Sc., Annemieke Cats, M.D., Ph.D., Hester J. van der Zaag-Loonen, M.D., Ph.D., Alexandra M. J. Langers, M.D., Ph.D., Jerry H. W. Bergmann, M.D., Paul C. van de Meeberg, M.D., Ph.D., Evelien Dekker, M.D., Ph.D., Jan H. Kleibeuker, M.D., Ph.D., Hans F. A. Vasen, M.D., Ph.D., Fokko M. Nagengast, M.D., Ph.D., Peter van Duijvendijk, M.D., Ph.D.
Risk of Colorectal Adenoma and Carcinoma After Colectomy for Colorectal Cancer in Patients Meeting Amsterdam Criteria
Matthew F. Kalady, MD, Ellen McGannon, BS, Jon D. Vogel, MD, Elena Manilich, PhD, Victor W. Fazio, MD, and James M. Church, MB, ChB
Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
Maxime J M van der Valk, Denise E Hilling, Esther Bastiaannet, Elma Meershoek-Klein Kranenbarg, Geerard L Beets, Nuno L Figueiredo, Angelita Habr-Gama, Rodrigo O Perez, Andrew G Renehan, Cornelis J H van de Velde, and the IWWD Consortium
Long-term outcome and prognostic factors for patients with para-aortic lymph node dissection in left-sided colorectal cancer
Kota Sahara, Jun Watanabe, Atsushi Ishibe, Yusuke Suwa, Hirokazu Suwa, Mitsuyoshi Ota, Chikara Kunisaki, Itaru Endo
Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers
Aung Ko Win, MBBS, MPH, Susan Parry, MB ChB, FRACP, Bryan Parry, MD, FRACS, Matthew F. Kalady, MD, Finlay A. Macrae, MBBS, MD, FRACP, FRCP, AGAF, Dennis J. Ahnen, MD, AGAF, Graeme P. Young, MBBS, MD, FRACP, FTSE, AGAF, Lara Lipton, PhD, FRACP, Ingrid Winship, MD ChB, MD, FRACP, Alex Boussioutas, MBBS, PhD, FRACP, Joanne P. Young, PhD, Daniel D. Buchanan, PhD, Julie Arnold, RN, Loïc Le Marchand, MD, PhD, Polly A. Newcomb, PhD, Robert W. Haile, DrPH, Noralane M. Lindor, MD, Steven Gallinger, MD, MSc, FRCSC, John L. Hopper, PhD, and Mark A. Jenkins, PhD1
Management of para-aortic lymph node metastasis in colorectal patients: A systemic review
J.S.M. Wong, G.H.C. Tan, M.C.C. Teo
Adrenocortical Carcinoma: Impact of Surgical Margin Status on Long-Term Outcomes
Georgios Antonios Margonis, MD, PhD, Yuhree Kim, MD, MPH, Jason D. Prescott, MD, PhD, Thuy B. Tran, MD, Lauren M. Postlewait, MD, Shishir K. Maithel, MD, Tracy S. Wang, MD, MPH, Douglas B. Evans, MD, Ioannis Hatzaras, MD, MPH, Rivfka Shenoy, MD, John E. Phay, MD, Kara Keplinger, MD, Ryan C. Fields, MD, Linda X. Jin, MD, Sharon M. Weber, MD, Ahmed Salem, MD, Jason K. Sicklick, MD, Shady Gad, MD, Adam C. Yopp, MD, John C. Mansour, MD, Quan-Yang Duh, MD, Natalie Seiser, MD, PhD, Carmen C. Solorzano, MD, Colleen M. Kiernan, MD, Konstantinos I. Votanopoulos, MD, Edward A. Levine, MD, George A. Poultsides, MD, and Timothy M. Pawlik, MD, MPH, PhD
Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane
Elizabeth G. Grubbs, MD, Glenda G. Callender, MD, Yan Xing, MD, PhD, MS, Nancy D. Perrier, MD, Douglas B. Evans, MD, Alexandria T. Phan, MD, and Jeffrey E. Lee, MD
Evaluation, Staging, and Surgical Management for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group
Paxton V. Dickson, MD, Lawrence Kim, MD, Tina W. F. Yen, MD, MS, Anthony Yang, MD, Elizabeth G. Grubbs, MD, MS, Dhavel Patel, MD, FACS, and Carmen C. Solo´rzano, MD
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Jae Yong Cho, Jan H.M. Schellens, Jean Charles Soria, Patrick Y. Wen, Christoph Zielinski, Maria E. Cabanillas, Gladys Urbanowitz, Bijoyesh Mookerjee, Dazhe Wang, Fatima Rangwala, and Bhumsuk Keam
Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma
Sarika N. Rao,* Mark Zafereo,* Ramona Dadu,1 Naifa L. Busaidy, Kenneth Hess, Gilbert J. Cote, Michelle D. Williams, William N. William, Vlad Sandulache, Neil Gross, Brandon Gunn, Charles Lu, Renata Ferrarotto, Stephen Y. Lai, and Maria E. Cabanillas
A Systematic Review of Phase II Targeted Therapy
Clinical Trials in Anaplastic Thyroid Cancer
Josip Ljubas, Therese Ovesen, and Maria Rusan
Lanreotide in Metastatic Enteropancreatic
Neuroendocrine Tumors
Martyn E. Caplin, D.M., Marianne Pavel, M.D., Jarosław B. Ć wikła, M.D., Ph.D., Alexandria T. Phan, M.D., Markus Raderer, M.D., Eva Sedlačkova, M.D., Guillaume Cadiot, M.D., Ph.D., Edward M. Wolin, M.D., Jaume Capdevila, M.D., Lucy Wall, M.D., Guido Rindi, M.D., Ph.D., Alison Langley, M.Sc., Severine Martinez, B.Sc., Joelle Blumberg, M.D., and Philippe Ruszniewski, M.D., Ph.D., for the CLARINET Investigators*
Phase 3 Trial of 177Lu-Dotatate for Midgut
Neuroendocrine Tumors
Strosberg, G. El‑Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, Ruszniewski, D. Kwekkeboom, and E. Krenning, for the NETTER-1 Trial Investigators*
Prospective Study of 68Ga-DOTATATE Positron Emission
Tomography/Computed Tomography for Detecting
Gastro-Entero-Pancreatic Neuroendocrine Tumors
and Unknown Primary Sites
Samira M. Sadowski, Vladimir Neychev, CorinaMillo, Joanna Shih, Naris Nilubol, Peter Herscovitch, Karel Pacak, Stephen J. Marx, and Electron Kebebew
Fellows National Video Conference 2018
8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer
Vic J. Verwaal, MD, PhD,1 Sjoerd Bruin, MD,1 Henk Boot, MD, PhD,2 Gooike van Slooten,
MD,1 and Harm van Tinteren, ScM3
A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases
Dominique Elias, MD, PhD1, Matthieu Faron, MD3, Diane Goe´re´, MD, PhD1, Fre´de´ric Dumont, MD1, Charles Honore´, MD1, Vale´rie Boige, MD2, David Malka, MD2, and Michel Ducreux, MD, PhD2
Factors Associated with Lymph Node Metastasis in Radically Resected Rectal Carcinoids: a Systematic Review and Meta-analysis
Xin Zhou & Haiting Xie & Lingduo Xie & Jing Li & Wei Fu
Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial
Julio Garcia-Aguilar, Lindsay A Renfro, Oliver S Chow, Qian Shi, Xiomara W Carrero, Patricio B Lynn, Charles R Thomas Jr, Emily Chan, Peter A Cataldo, Jorge E Marcet, David S Medich, Craig S Johnson, Samuel C Oommen, Bruce G Wolff , Alessio Pigazzi, Shane M McNevin, Roger K Pons, Ronald Bleday
Peritoneal Colorectal Carcinomatosis Treated With Surgery and Perioperative Intraperitoneal Chemotherapy: Retrospective Analysis of 523 Patients From a Multicentric French Study
Dominique Elias, Franc¸ois Gilly, Florent Boutitie, Franc¸ois Quenet, Jean-Marc Bereder, Baudouin Mansvelt, Ge´rard Lorimier, Pierre Dube`, and Olivier Glehen
Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years
Rolf Sauer, Torsten Liersch, Susanne Merkel, Rainer Fietkau, Werner Hohenberger, Clemens Hess, Heinz Becker, Hans-Rudolf Raab, Marie-Therese Villanueva, Helmut Witzigmann, Christian Wittekind, Tim Beissbarth, and Claus Ro¨del
Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer
By Vic J. Verwaal, Serge van Ruth, Eelco de Bree, Gooike W. van Slooten, Harm van Tinteren, Henk Boot, and Frans A.N. Zoetmulder
Surgical management of rectal carcinoids: trends and outcomes from the Surveillance, Epidemiology, and End Results database (1988 to 2012)
Yarrow J. McConnell, M.D., M.Sc., F.R.C.S.C.*
Department of Surgery, University of British Columbia, 5th Floor, 2775 Laurel St., Vancouver, British Columbia, V5Z 1M9, Canada
Surveillance of Small Rectal Carcinoid Tumors in the Absence of Metastatic Disease
Sara E. Murray, MD1, Rebecca S. Sippel, MD, FACS1, Ricardo Lloyd, MD, PhD2, and Herbert Chen, MD, FACS1
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis
Andrew G Renehan, Lee Malcomson, Richard Emsley, Simon Gollins, Andrew Maw, Arthur Sun Myint, Paul S Rooney, Shabbir Susnerwala, Anthony Blower, Mark P Saunders, Malcolm S Wilson, Nigel Scott, Sarah T O’Dwyer
Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma
Brendon G. Conry & Nikolaos D. Papathanasiou & Vineet Prakash & Irfan Kayani & Martyn Caplin & Shahid Mahmood & Jamshed B. Bomanji
Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials
Y. Ito, A. Miyauchi*, H. Oda
The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis
Aslam Ejaz MD1 | Brad N. Reames MD1 | Shishir Maithel MD2 | George A. Poultsides MD3 | Todd W. Bauer MD4 | Ryan C. Fields MD5 | Matt Weiss MD1 | Hugo Pinto Marques MD6 | Luca Aldrighetti MD7 | Timothy M. Pawlik MD, MPH, PhD8
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance
R. Michael Tuttle, MD; James A. Fagin, MD; Gerald Minkowitz, MD; Richard J.Wong, MD;Benjamin Roman, MD, MSHP; Snehal Patel, MD; Brian Untch, MD; Ian Ganly,MD, PhD; Ashok R. Shaha, MD; Jatin P. Shah, MD; Mark Pace, MBBS, FRACP; Duan Li, MD; Ariadne Bach, MD; Oscar Lin, MD; Adrian Whiting, BS; Ronald Ghossein, MD; Inigo Landa, PhD; Mona Sabra, MD; Laura Boucai, MD; Stephanie Fish, MD; Luc G. T. Morris, MD, MSc
Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study
Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo, Paolo Miccoli, Piero Berti, Furio Pacini, and Aldo Pinchera
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg, G. El‑Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen, E. Mittra, P.L. Kunz, M.H. Kulke, H. Jacene, D. Bushnell, T.M. O’Dorisio, R.P. Baum, H.R. Kulkarni, M. Caplin, R. Lebtahi, T. Hobday, E. Delpassand, E. Van Cutsem, A. Benson, R. Srirajaskanthan, M. Pavel, J. Mora, J. Berlin, E. Grande, N. Reed, E. Seregni, K. Öberg, M. Lopera Sierra, P. Santoro, T. Thevenet, J.L. Erion, P. Ruszniewski, D. Kwekkeboom, and E. Krenning, for the NETTER-1 Trial Investigators*
Emerging Approaches in the Management of Patients with Neuroendocrine Liver Metastasis: Role of Liver-Directed and Systemic Therapies
Skye C Mayo, MD, MPH, Joseph M Herman, MD, MSc, David Cosgrove, MD, Nik Bhagat, MD,
Ihab Kamel, MD, Jean-Francois H Geschwind, MD, Timothy M Pawlik, MD, MPH, PhD, FACS
Long-term Results of Reoperation and Localizing Studies in Patients with Persistent or Recurrent Medullary Thyroid Cancer
Electron Kebebew, Md; Shoichi Kikuchi, MD, PhD; Quan-Yang Duh, MD; Orlo H. Clark, MD
Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis
Salvatore Vaccarella, Ph.D., Silvia Franceschi, M.D., Freddie Bray, Ph.D., Christopher P. Wild, Ph.D., Martyn Plummer, Ph.D., and Luigino Dal Maso, Ph.D.
Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses
Se Hoon Park, Tae Sung Sohn, Jeeyun Lee, Do Hoon Lim, Min Eui Hong, Kyoung-Mee Kim, Insuk Sohn, Sin Ho Jung, Min Gew Choi, Jun Ho Lee, Jae Moon Bae, Sung Kim, Seung Tae Kim, Joon Oh Park, Young Suk Park, Ho Yeong Lim, and Won Ki Kang
Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial
Annemieke Cats*, Edwin P M Jansen*, Nicole C T van Grieken, Karolina Sikorska, Pehr Lind, Marianne Nordsmark, Elma Meershoek-Klein Kranenbarg, Henk Boot, Anouk K Trip, H A Maurits Swellengrebel, Hanneke W M van Laarhoven, Hein Putter, Johanna W van Sandick,
Mark I van Berge Henegouwen, Henk H Hartgrink, Harm van Tinteren, Cornelis J H van de Velde†, Marcel Verheij†, for the CRITICS investigators
Efficacy of Adjuvant Chemotherapy for Small Bowel Adenocarcinoma: A Propensity Score–Matched Analysis
Aslam Ejaz MD1 | Brad N. Brett L. Ecker, MD1; Matthew T. McMillan, BA1; Jashodeep Datta, MD1; Ronac Mamtani, MD, MSCE2; Bruce J. Giantonio, MD2; Daniel T. Dempsey, MD1; Douglas L. Fraker, MD1; Jeffrey A. Drebin, MD, PhD1; Giorgos C. Karakousis, MD1; and Robert E. Roses, MD1
Patterns of Recurrence After Surgery Alone Versus Preoperative Chemoradiotherapy and Surgery in the CROSS Trials
Vera Oppedijk, Ate van der Gaast, Jan J.B. van Lanschot, Pieter van Hagen, Rob van Os, Caroline M. van Rij, Maurice J. van der Sangen, Jannet C. Beukema, Heidi Ru¨tten, Patty H. Spruit, Janny G. Reinders, Dick J. Richel, Mark I. van Berge Henegouwen, and Maarten C.C.M. Hulshof
North Central Cancer Treatment Group N0543 (Alliance): A Phase 2 Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Patients With Advanced Small Bowel Adenocarcinoma
Robert R. McWilliams, MD 1; Nathan R. Foster, MS2; Michelle R. Mahoney, MS2; Thomas C. Smyrk, MD3; Joseph A. Murray, MD4; Matthew M. Ames, PhD5; L. Elise Horvath, MD6; Daniel J. Schneider, MD7; Timothy J. Hobday, MD1; Aminah Jatoi, MD 1; Jeffrey P. Meyers, BA2; and Matthew P. Goetz, MD
NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
Somnath Mukherjee a,1, Christopher Nicholas Hurt b,*,1, Sarah Gwynne c, David Sebag-Montefiore d, Ganesh Radhakrishna d, Simon Gollins e, Maria Hawkins a, Heike I. Grabsch f,g, Gareth Jones h, Stephen Falk i, Ricky Sharma a, Andrew Bateman j, Rajarshi Roy k, Ruby Ray b,Jo Canham b, Gareth Griffiths l, Tim Maughan a, Tom Crosby
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial
Elizabeth C. Smyth, Matteo Fassan, David Cunningham, William H. Allum, Alicia F.C. Okines, Andrea Lampis, Jens C. Hahne,Massimo Rugge, Clare Peckitt,Matthew Nankivell, Ruth Langley,Michele Ghidini, Chiara Braconi, Andrew Wotherspoon, Heike I. Grabsch, and Nicola Valeri
Patients with Adenocarcinoma of the Small Intestine with 9 or More Regional Lymph Nodes Retrieved Have a Higher Rate of Positive Lymph Nodes and Improved Survival
Alexander Wilhelm1 & Sascha A. Müller1 & Thomas Steffen1 & Bruno M. Schmied1 &
Ulrich Beutner1 & Rene Warschkow1,2
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fl uorouracil, and leucovorin versus epirubicin, cisplatin, and fl uorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Salah-Eddin Al-Batran, Ralf D Hofh einz, Claudia Pauligk, Hans-Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk M Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfi tsch, Martin Schuler, Wolf O Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten O Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
Kristine R. Broglio, MS; Melanie Quintana, PhD; Margaret Foster, MS; Melissa Olinger, BA; Anna McGlothlin, PhD; ScottM. Berry, PhD; Jean-François Boileau, MD; Christine Brezden-Masley, MD; Stephen Chia, MD; Susan Dent, MD; Karen Gelmon, MD; Alexander Paterson, MD; Daniel Rayson, MD; Donald A. Berry, PhD
Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer
Lucy M. De La Cruz, MD1 and Brian J. Czerniecki, MD, PhD
Adaptive Randomization of Veliparib– Carboplatin Treatment in Breast Cancer
H.S. Rugo, O.I. Olopade, A. DeMichele, C. Yau, L.J. van ‘t Veer, M.B. Buxton, M. Hogarth, N.M. Hylton, M. Paoloni, J. Perlmutter, W.F. Symmans, D. Yee, A.J. Chien, A.M. Wallace, H.G. Kaplan, J.C. Boughey, T.C. Haddad, K.S. Albain, M.C. Liu, C. Isaacs, Q.J. Khan, J.E. Lang, R.K. Viscusi, L. Pusztai, S.L. Moulder, S.Y. Chui, K.A. Kemmer, A.D. Elias, K.K. Edmiston, D.M. Euhus, B.B. Haley,R. Nanda, D.W. Northfelt, D. Tripathy, W.C. Wood, C. Ewing, R. Schwab, J. Lyandres, S.E. Davis, G.L. Hirst, A. Sanil, D.A. Berry, and L.J. Esserman, for the I-SPY 2 Investigators
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment
S. Dawood1, S. D. Merajver2, P. Viens3, P. B. Vermeulen4, S. M. Swain5, T. A. Buchholz6, L. Y. Dirix7, P. H. Levine8, A. Lucci9, S. Krishnamurthy10, F. M. Robertson11, W. A. Woodward6, W. T. Yang12, N. T. Ueno13 & M. Cristofanilli
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im, M.D., Roberto Hegg, M.D., Young-Hyuck Im, M.D., Laslo Roman, M.D., José Luiz Pedrini, M.D., Tadeusz Pienkowski, M.D., Adam Knott, Ph.D., Emma Clark, M.Sc., Mark C. Benyunes, M.D., Graham Ross, F.F.P.M., and Sandra M. Swain, M.D., for the CLEOPATRA Study Group*
Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer
Carolyn S. Hall, Mandar Karhade, Barbara A. Laubacher, Henry M. Kuerer, Savitri Krishnamurthy, Sarah DeSnyder, Amber E. Anderson, Vicente Valero, Naoto T. Ueno, Yisheng Li, Xiao Su, Anthony Lucci
Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
Judy C. Boughey, MD; Vera J. Suman, PhD; Elizabeth A. Mittendorf, MD, PhD; Gretchen M. Ahrendt, MD; Lee G. Wilke, MD; Bret Taback, MD; A. Marilyn Leitch, MD; HenryM. Kuerer,MD, PhD; Monet Bowling, MD; Teresa S. Flippo-Morton, MD; David R. Byrd, MD; DavidW. Ollila, MD; Thomas B. Julian, MD; Sarah A. McLaughlin, MD; Linda McCall, MS;W. Fraser Symmans, MD; Huong T. Le-Petross, MD; Bruce G. Haffty, MD; Thomas A. Buchholz, MD; Heidi Nelson, MD; Kelly K. Hunt, MD; for the Alliance for Clinical Trials in Oncology
Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0–T4, N1–N2) Who Receive Neoadjuvant Chemotherapy
Judy C. Boughey, MD,_ Karla V. Ballman, PhD,y Huong T. Le-Petross, MD,z Linda M. McCall,§Elizabeth A. Mittendorf, MD, PhD,_ Gretchen M. Ahrendt, MD,jj Lee G. Wilke, MD, Bret Taback, MD,yy Eric C. Feliberti, MD,zz and Kelly K. Hunt, MD
Postmastectomy Radiation in Breast Cancer Patients With Pathologically Positive Lymph Nodes After Neoadjuvant Chemotherapy: Usage Rates and Survival Trends
Nisha Ohri, MD,* Erin Moshier, MS, y Alice Ho, MD, MBA, z Sheryl Green, MD,* Ryan Rhome, MD, PhD,* Madhu Mazumdar, PhD Y Simon Powell, MD, PhD, x and Chiaojung Jillian Tsai, MD, PhD
Fellows National Video Conference 2017
Neoadjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Ronald P DeMatteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein,Charles D Blanke, Margaret von Mehren, Murray F Brennan, Shreyaskumar Patel, Martin D McCarter, Jonathan A Polikoff , Benjamin R Tan, Kouros Owzar, on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-Institutional Analysis
Fabian M. Johnston, MD1, Peter J. Kneuertz, MD1, John L. Cameron, MD1, Dominic Sanford, MD2, Sarah Fisher, MD3, Ryan Turley, MD4, Ryan Groeschl, MD5, Omar Hyder, MD1, David A. Kooby, MD3, Dan Blazer III , MD4, Michael A. Choti, MD1, Christopher L. Wolfgang, MD, PhD1, T. Clark Gamblin, MD5, William G. Hawkins, MD2, Shishir K. Maithel, MD3, and Timothy M. Pawlik, MD, MPH, PhD1
A Systematic Review and Meta-analysis Comparing Pancreaticoduodenectomy Versus Limited Resection for Duodenal Gastrointestinal Stromal Tumors
Aik-Yong Chok, MBBS1, Ye-Xin Koh, MBBS1, Mandy Y. L. Ow, PhD2, John C. Allen Jr., PhD2, and Brian K. P. Goh, MBBS, MMed, MSc, FRCS1,2
Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment
George A. Poultsides, MD1,2, Lyen C. Huang, MD, MPH2, John L. Cameron, MD1, Richard Tuli, MD, PhD3, Leslie Lan, MPH, MBA4,5,7, Ralph H. Hruban, MD6, Timothy M. Pawlik, MPH, MBA1, Joseph M. Herman, MD, MSc3, Barish H. Edil, MD1, Nita Ahuja, MD1, Michael A. Choti, MD, MBA1, Christopher L. Wolfgang, MD, PhD1, and Richard D. Schulick, MD, MBA1
Does the Extent of Resection Impact Survival for Duodenal Adenocarcinoma? Analysis of 1,611 Cases
Jordan M. Cloyd, MD, Jeffrey A. Norton, MD, Brendan C. Visser, MD, and George A. Poultsides, MD
15-Year Experience with Surgical Treatment of Duodenal Carcinoma: a Comparison of Periampullary and Extra-Ampullary Duodenal Carcinomas
Edwin O. Onkendi & Sarah Y. Boostrom & Michael G. Sarr & Michael B. Farnell & David M. Nagorney & John H. Donohue & Michael L. Kendrick & Kaye M. Reid-Lombardo & William S. Harmsen & Florencia G. Que
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center Postsurgical Outcomes in 41 Patients
Vivian E. Strong, MD, Sepideh Gholami, MD, Manish A. Shah, MD, Laura H. Tang, MD, PhD, Yelena Y. Janjigian, MD, Mark Schattner, MD, Luke V. Selby, MD, Sam S. Yoon, MD, Erin Salo-Mullen, MS, CGC, Zsofia K. Stadler, MD, David Kelsen, MD, Murray F. Brennan, MD, and Daniel G. Coit, MD
Hereditary Diffuse Gastric Cancer Syndrome CDH1 Mutations and Beyond
Samantha Hansford, MSc; Pardeep Kaurah, MSc; Hector Li-Chang, MD; MichelleWoo, PhD; Janine Senz, BSc; Hugo Pinheiro, PhD; Kasmintan A. Schrader, MBBS, PhD; David F. Schaeffer, MD; Karey Shumansky, MSc; George Zogopoulos, MD; Teresa Almeida Santos, MD, PhD; Isabel Claro, MD; Joana Carvalho, PhD; Cydney Nielsen, PhD; Sarah Padilla, BSc; Amy Lum, BSc; Aline Talhouk, PhD; Katie Baker-Lange, MSc; Sue Richardson, RGN; Ivy Lewis, BN, RN; Noralane M. Lindor, MD; Erin Pennell, RN; Andree MacMillan, MSc; Bridget Fernandez, MD; Gisella Keller, PhD; Henry Lynch, MD; Sohrab P. Shah, PhD; Parry Guilford, MSc, PhD; Steven Gallinger, MD; Giovanni Corso,MD, PhD; Franco Roviello, MD; Carlos Caldas, MD; Carla Oliveira, PhD; Paul D. P. Pharoah, PhD; David G. Huntsman, MD
Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance
Yean Cheant Lim, MBChB, MRCP,1 Massimiliano di Pietro, MD,2 Maria O’Donovan, MD, FRCPath,3 Susan Richardson, RGN,4 Irene Debiram, MSc,4 Susan Dwerryhouse, MSc,5 Richard H. Hardwick, MD, FRCS,5 Marc Tischkowitz, PhD, MRCP,6 Carlos Caldas, MD, FMedSci,2 Krish Ragunath, MD, FRCP,7 Rebecca C. Fitzgerald, MD, FMedSci2
Society of Surgical Oncology–American Society for Radiation Oncology–American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ
Monica Morrow, Kimberly J. Van Zee, Lawrence J. Solin, Nehmat Houssami, Mariana Chavez-MacGregor, Jay R. Harris, Janet Horton, Shelley Hwang, Peggy L. Johnson, M. Luke Marinovich, Stuart J. Schnitt, Irene Wapnir, and Meena S. Moran
Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ: Analysis of 2996 Women Treated With Breast-conserving Surgery for 30 Years
Kimberly J. Van Zee, MS, MD, FACS, Preeti Subhedar, MD, Cristina Olcese, BS, Sujata Patil, PhD, and Monica Morrow, MD, FACS
Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study
Lawrence J. Solin, Robert Gray, Lorie L. Hughes, William C. Wood, Mary Ann Lowen, Sunil S. Badve, Frederick L. Baehner, James N. Ingle, Edith A. Perez, Abram Recht, Joseph A. Sparano, and Nancy E. Davidson
Prognosis of Women With Primary Breast Cancer Diagnosed During Pregnancy: Results From an International Collaborative Study
Fre´de´ric Amant, Gunter von Minckwitz, Sileny N. Han, Marijke Bontenbal, Alistair E. Ring, Jerzy Giermek, Hans Wildiers, Tanja Fehm, Sabine C. Linn, Bettina Schlehe, Patrick Neven, Pieter J. Westenend, Volkmar Mu¨ller, Kristel Van Calsteren, Brigitte Rack, Valentina Nekljudova, Nadia Harbeck, Michael Untch, Petronella O. Witteveen, Kathrin Schwedler, Christoph Thomssen, Ben Van Calster, and Sibylle Loibl
Sentinel Lymph Node Biopsy in Pregnant Women with Breast Cancer
Adrienne B. Gropper, MD1, Katherina Zabicki Calvillo, MD1, Laura Dominici, MD1, Susan Troyan, MD1, Esther Rhei, MD1, Katherine E. Economy, MD2, Nadine M. Tung, MD3, Lidia Schapira, MD4, Jane L. Meisel, MD1, Ann H. Partridge, MD, MPH1, and Erica L. Mayer, MD, MPH
Breast Cancer in Pregnancy: Avoiding Fetal Harm When Maternal Treatment Is Necessary
Christina N. Cordeiro, MD,* and Mary L. Gemignani, MD, MPH
Contralateral mastectomy and survival after breast
cancer in carriers of BRCA1 and BRCA2 mutations:
retrospective analysis
Kelly Metcalfe, Shelley Gershman, Parviz Ghadirian, Henry T Lynch, Carrie Snyder, Nadine Tung, Charmaine Kim-Sing, Andrea Eisen, William D Foulkes, Barry Rosen, Ping Sun, Steven A Narod
Nipple sparing mastectomy: Surgical and oncological outcomes from a national multicentric registry with 913 patients (1006 cases) over a six year period
Lorenzo Orzalesi, Donato Casella, Caterina Santi, Lorenzo Cecconi, Roberto Murgo, Stefano Rinaldi, Lea Regolo e, Claudio Amanti, Manuela Roncella, Margherita Serra,
Graziano Meneghini, Massimiliano Bortolini, Vittorio Altomare, Carlo Cabula,
Francesca Catalano, Alfredo Cirilli, Francesco Caruso, Maria Grazia Lazzaretti,
Luigi Cataliotti, Marco Bernini
Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers
Nadine Tung • Elizabeth Gaughan • Michele R. Hacker •Larissa J. Lee • Brian Alexander • Emily Poles • Stuart J. Schnitt • Judy E. Garber
Radiation Monotherapy as Regional Treatment for Lymph Node-Positive Merkel Cell Carcinoma
L. Christine Fang, MD1; Bianca Lemos, MD2; James Douglas, MD1,3; Jayasri Iyer, MD2; and Paul Nghiem, MD, PhD2,3
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L Kaufman, Jeffery Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P D’Angelo, Kent C Shih, Céleste Lebbé, Gerald P Linette, Michele Milella, Isaac Brownell, Karl D Lewis, Jochen H Lorch, Kevin Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem
Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution
Peter J. Allen, Wilbur B. Bowne, David P. Jaques, Murray F. Brennan, Klaus Busam, and Daniel G. Coit
Outcome and Prognostic Factor Analysis of 217 Consecutive Isolated Limb Perfusions with Tumor Necrosis Factor_- and Melphalan for Limb-Threatening Soft Tissue Sarcoma
Dirk J. Grunhagen, M.D., Johannes H. W. de Wilt, M.D., Ph.D., Wilfried J. Graveland, M.Sc, Cornelis Verhoef, M.D., Albertus N. van Geel, M.D., Ph.D., Alexander M. M. Eggermont, M.D., Ph.D.
Randomized Prospective Study of the Benefit of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcomas of the Extremity
James C. Yang, Alfred E. Chang, Alan R. Baker, William F. Sindelar, David N. Danforth, Suzanne L. Topalian,Thomas DeLaney, Eli Glatstein, Seth M. Steinberg, Maria J. Merino, and Steven A. Rosenberg
Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes
Janice N. Cormier, Xuelin Huang, Yan Xing, Peter F. Thall, Xuemei Wang, Robert S. Benjamin, Raphael E. Pollock, Cristina R. Antonescu, Robert G. Maki, Murray F. Brennan, and Peter W.T. Pisters
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A.M.M. Eggermont, V. Chiarion‑Sileni, J.-J. Grob, R. Dummer, J.D. Wolchok, H. Schmidt, O. Hamid, C. Robert, P.A. Ascierto, J.M. Richards, C. Lebbe, V. Ferraresi, M. Smylie, J.S. Weber, M. Maio, L. Bastholt, L. Mortier, L. Thomas, S. Tahir, A. Hauschild, J.C. Hassel, F.S. Hodi, C. Taitt, V. de Pril, G. de Schaetzen,S. Suciu, and A. Testori
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
Ahmad A. Tarhini1*, Howard Edington2, Lisa H. Butterfield1, Yan Lin3, Yongli Shuai3, Hussein Tawbi1, Cindy Sander1, Yan Yin1, Matthew Holtzman4, Jonas Johnson5, Uma N. M. Rao6, John M. Kirkwood
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, M.D., Steven J. O’Day, M.D., David F. McDermott, M.D., Robert W. Weber, M.D., Jeffrey A. Sosman, M.D., John B. Haanen, M.D., Rene Gonzalez, M.D., Caroline Robert, M.D., Ph.D., Dirk Schadendorf, M.D., Jessica C. Hassel, M.D., Wallace Akerley, M.D., Alfons J.M. van den Eertwegh, M.D., Ph.D., Jose Lutzky, M.D., Paul Lorigan, M.D., Julia M. Vaubel, M.D., Gerald P. Linette, M.D., Ph.D., David Hogg, M.D., Christian H. Ottensmeier, M.D., Ph.D., Celeste Lebbe, M.D., Christian Peschel, M.D., Ian Quirt, M.D., Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D., Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D.
Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma
John E Mullinax, MD, Hidde M Kroon, MD, PhD, John F Thompson, MD, FACS, Neel Nath, BS, Paul J Mosca, MD, PhD, FACS, Jeffrey M Farma, MD, FACS, Rajendra Bhati, MD, FACS, Danielle Hardmann, BS, Sean Sileno, BS, Cristina O’Donoghue, MD, Matthew Perez, MD, Syeda Mahrukh Hussnain Naqvi, MD, Y Ann Chen, PhD, Ricardo J Gonzalez, MD, FACS, Jonathan S Zager, MD, FACS
415 Patients with Adenosquamous Carcinoma of the Pancreas: A Population-Based Analysis of Prognosis and Survival
Casey A. Boyd, M.D., Jaime Benarroch-Gampel, M.D., Kristin M. Sheffield, Ph.D.,Catherine D. Cooksley, Dr.P.H., and Taylor S. Riall, M.D., Ph.D.1
Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification
J. W. Gilbert1,2,3*, B. Wolpin3,4, T. Clancy3,5, J. Wang3,5,6, H. Mamon3,7, A. B. Shinagare1,2,3, J. Jagannathan1,2,3 & M. Rosenthal1,2,3
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label,randomised, phase 3 trial
John P Neoptolemos, Daniel H Palmer, Paula Ghaneh, Eftychia E Psarelli, Juan W Valle, Christopher M Halloran, Olusola Faluyi, Derek A O’Reilly, David Cunningham, Jonathan Wadsley, Suzanne Darby, Tim Meyer, Roopinder Gillmore, Alan Anthoney, Pehr Lind, Bengt Glimelius, Stephen Falk, Jakob R Izbicki, Gary William Middleton, Sebastian Cummins, Paul J Ross, Harpreet Wasan, Alec McDonald, Tom Crosby, Yuk Ting Ma, Kinnari Patel, David Sherriff, Rubin Soomal, David Borg, Sharmila Sothi, Pascal Hammel, Thilo Hackert, Richard Jackson, Markus W Büchler, for the European Study Group for Pancreatic Cancer
Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time Period
Sébastien Gaujoux, MD, PhD, Murray F Brennan, MD, FACS, Mithat Gonen, PhD, Michael I D’Angelica, MD, FACS, Ronald DeMatteo, MD, FACS, Yuman Fong, MD, FACS, Mark Schattner, MD, Christopher DiMaio, MD, Maria Janakos, BS, William R Jarnagin, MD, FACS, Peter J Allen, MD, FACS
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
Masao Tanaka a,*, Carlos Fernández-del Castillo b, Volkan Adsay c, Suresh Chari d, Massimo Falconi e, Jin-Young Jang f, Wataru Kimura g, Philippe Levy h, Martha Bishop Pitman i, C. Max Schmidt j, Michio Shimizu k, Christopher L. Wolfgang l, Koji Yamaguchim, Kenji Yamao n
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A021101
Matthew H. G. Katz, MD; Qian Shi, PhD; Syed A. Ahmad, MD; Joseph M. Herman, MD; Robert deW. Marsh, MD; Eric Collisson, MD; Lawrence Schwartz, MD;Wendy Frankel, MD; Robert Martin, MD; William Conway, MD; Mark Truty, MD; Hedy Kindler, MD; Andrew M. Lowy, MD; Tanios Bekaii-Saab, MD; Philip Philip,MD, PhD; Mark Talamonti, MD; Dana Cardin, MD; Noelle LoConte, MD; Perry Shen, MD; John P. Hoffman, MD; Alan P. Venook, MD
Presentation and Management of Gastrointestinal Stromal Tumors of the Duodenum: A Multi-Institutional Analysis
Fabian M. Johnston, MD1, Peter J. Kneuertz, MD1, John L. Cameron, MD1, Dominic Sanford, MD2, Sarah Fisher, MD3, Ryan Turley, MD4, Ryan Groeschl, MD5, Omar Hyder, MD1, David A. Kooby, MD3, Dan Blazer III , MD4, Michael A. Choti, MD1, Christopher L. Wolfgang, MD, PhD1, T. Clark Gamblin, MD5, William G. Hawkins, MD2, Shishir K. Maithel, MD3, and Timothy M. Pawlik, MD, MPH, PhD1
Results of Tyrosine Kinase Inhibitor Therapy Followed by Surgical Resection for Metastatic Gastrointestinal Stromal Tumor
Ronald P. DeMatteo, MD,* Robert G. Maki, MD, PhD,§ Samuel Singer, MD,* Mithat Gonen, PhD,† Murray F. Brennan, MD,* and Cristina R. Antonescu, MD‡
Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor
Ser Yee Lee, MD, MSc, MMed, FRCS(Ed)1,2,3, Brian K. P. Goh, MBBS, MSc, MMed, FRCS(Ed)2,3, Eran Sadot, MD1, Rahul Rajeev, MBBS1, Vinod P. Balachandran, MD1, Mithat Go¨nen, PhD4, T. Peter Kingham, MD1, Peter J. Allen, MD1, Michael I. D’Angelica, MD1, William R. Jarnagin, MD1, Daniel Coit, MD1, Wai Keong Wong, MBBS, FRCS3,5, Hock Soo
Fellows National Video Conference 2016
Efficacy of Repeat Sentinel Lymph Node Biopsy in Patients Who Develop Recurrent Melanoma
Georgia M Beasley, MD, Paul Speicher, MD, Ketan Sharma, MD, Hilliard Seigler, MD, FACS, April Salama, MD, Paul Mosca, MD, PhD, FACS, Douglas S Tyler, MD, FACS
Surgical Management of the Groin Lymph Nodes in Melanoma in the Era of Sentinel Lymph Node Dissection
Richard Essner, MD; Randall Scheri, MD; Maihgan Kavanagh, MD; Hitoe Torisu-Itakura, MD, PhD; Leslie A. Wanek, DrPH, MD; Donald L. Morton, MD
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, M.D., Steven J. O’Day, M.D., David F. McDermott, M.D., Robert W. Weber, M.D., Jeffrey A. Sosman, M.D., John B. Haanen, M.D., Rene Gonzalez, M.D., Caroline Robert, M.D., Ph.D., Dirk Schadendorf, M.D., Jessica C. Hassel, M.D., Wallace Akerley, M.D., Alfons J.M. van den Eertwegh, M.D., Ph.D., Jose Lutzky, M.D., Paul Lorigan, M.D., Julia M. Vaubel, M.D., Gerald P. Linette, M.D., Ph.D., David Hogg, M.D., Christian H. Ottensmeier, M.D., Ph.D., Celeste Lebbe, M.D., Christian Peschel, M.D., Ian Quirt, M.D., Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D., Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D.
Adjuvant Radiation Therapy is Associated With Improved Survival in Merkel Cell Carcinoma of the Skin
Pablo Mojica, David Smith, and Joshua D.I. Ellenhorn
Relationships between primary tumor size, number of involved nodes and survival among 8,044 cases of Merkel cell carcinoma
JG Iyer1, BE Storer2, KG Paulson1, B Lemos1,3, JL Phillips4, C Bichakjian6, N Zeitouni7, JE Gershenwald8, V Sondak9, CC Otley10, SS Yu11, TM Johnson6, NJ Liegeois12, D Byrd13,14, A Sober5, and P Nghiem1,2,13
Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms
Kiran K. Turaga, MD, MPH, Georgia M. Beasley, MD, John M. Kane III, MD, Keith A. Delman, MD, Stephen R. Grobmyer, MD, Ricardo J. Gonzalez, MD, G. Douglas Letson, MD, David Cheong, MD, Douglas S. Tyler, MD, and Jonathan S. Zager, MD
Pathologic Complete Response to Intralesional Interleukin-2 Therapy Associated with Improved Survival in Melanoma Patients with In-Transit Disease
Saima Hassan, MD, PhD, FRCSC1,2, Teresa M. Petrella, MD, MSc, FRCPC3, Tong Zhang, MSc4, Suzanne Kamel-Reid, BA, MA, PhD, FACMG4, Francesco Nordio, PhD5, Andrea Baccarelli, MD, PhD6, Shachar Sade, MD, MSc, FRCPC7, Karen Naert, MD, FRCPC4, Ayman Al Habeeb, MBBS, FRCPC4, Danny Ghazarian, MB ChB, PhD, FRCPC, FCAP4, and Frances C. Wright, MD, MEd, FRCSC1
Current Trends in Regional Therapy for Melanoma: Lessons Learned from 225 Regional Chemotherapy Treatments between 1995 and 2010 at a Single Institution
Amanda K Raymond, BS1, Georgia M Beasley, MD1, Gloria Broadwater, MS2, Christina K Augustine, PhD1, James C Padussis, MD1, Ryan Turley, MD1, Bercedis Peterson, PhD3, Hilliard Seigler, MD, FACS1, Scott K Pruitt, MD, PhD, FACS1, and Douglas S Tyler, MD, FACS1
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances Collichio, Thomas Amatruda, Neil Senzer, Jason Chesney, Keith A. Delman, Lynn E. Spitler, Igor Puzanov, Sanjiv S. Agarwala, Mohammed Milhem, Lee Cranmer, Brendan Curti, Karl Lewis, Merrick Ross, Troy Guthrie, Gerald P. Linette, Gregory A. Daniels, Kevin Harrington, Mark R. Middleton, Wilson H. Miller Jr, Jonathan S. Zager, Yining Ye, Bin Yao, Ai Li, Susan Doleman, Ari VanderWalde, Jennifer Gansert, and Robert S. Coffin
Role of Neoadjuvant Chemotherapy in Resectable Synchronous Colorectal Liver Metastasis; an International Multi-Center Data Analysis Using Livermetsurvey
Glenn K. Bonney, FRCS, Chris Coldham, Rene Adam, PhD, MD, Gernot Kaiser, FACS, MD, Eduardo Barroso, MD, Lorenzo Capussotti, MD, Christophe Laurent, MD, Cees Verhoef, PhD, MD, Gennaro Nuzzo, MD, Dominique Elias, MD, Real Lapointe, MD, Catherine Hubert, MD, Santiago Lopez-Ben, MD, Marek Krawczyk, MD, Darius F. Mirza, MS, FRCS, and on behalf of the Livermetsurvey International Registry Working Group
Role of Caudate Lobectomy in Type IIIA and IIIB Hilar Cholangiocarcinoma: A 15-year Experience in a Tertiary Institution
Alfred Wei-Chieh Kow, Choi Dong Wook, Sun Choon Song, Woo Seok Kim, Min Jung Kim, Hyo Jun Park, Jin Soek Heo, Seong Ho Choi
A Systematic Review: Treatment and Prognosis of Patients with Fibrolamellar Hepatocellular Carcinoma
Michael N Mavros, MD, Skye C Mayo, MD, MPH, Omar Hyder, MD, MS, Timothy M. Pawlik, MD, FACS, MPH, PhD
Differentiating Immunoglobulin G4-Related Sclerosing Cholangitis from Hilar Cholangiocarcinoma
Taku Tabata, Terumi Kamisawa, Seiichi Hara, Sawako Kuruma, Kazuro Chiba, Go Kuwata, Takashi Fujiwara, Hideto Egashira, Koichi Koizumi, Junko Fujiwara, Takeo Arakawa, Kumiko Momma, Masanao Kurata, Goro Honda, Koji Tsuruta, and Takao Itoi
Natural History and Treatment Trends in Hepatocellular Carcinoma Subtypes: Insights From a National Cancer Registry
Peter L. Jernigan, MD, Koffi Wima, MS, Dennis J. Hanseman, PhD, Richard S. Hoehn, MD, Syed A. Ahmad, MD, Shimul A. Shah, MD MHCM, and Daniel E. Abbott, MD
Synchronous Colorectal Liver Metastasis: A Network Meta-Analysis Review Comparing Classical, Combined, and Liver-First Surgical Strategies
M.E. Kelly, BA, MB, BCB, BAO, MRCS, G. Spolverato, MD, G.N. Lê, BA, MB, BCH, BAO, MRCP, M.N. Mavros, MD, F. Doyle, PhD, T.M. Pawlik, MD, PhD FACS, and D.C. Winter, MD, FRCS
Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection
Universe Leung, MBChB, Mithat Gönen, PhD, Peter J. Allen, MD, T. Peter Kingham, MD, Ronald P. DeMatteo, MD, William R. Jarnagin, MD, and Michael I. D’Angelica, MD
Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review
Patryk Kambakamba, M.D., Michael Linecker, M.D., Ksenija Slankamenac, M.D., Ph.D., Michelle L. DeOliveira, M.D., F.A.C.S.
Symptomatic Perihepatic Fluid Collections After Hepatic Resection in the Modern Era
Ioannis T. Konstantinidis & Pedro Mastrodomenico & Constantinos T. Sofocleous & Karen T. Brown & George I. Getrajdman & Mithat Gönen & Peter J. Allen1 & T. Peter Kingham & Ronald P. DeMatteo & Yuman Fong & William R. Jarnagin & Michael I. D’Angelica
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Claus Rödel*, Ullrich Graeven*, Rainer Fietkau, Werner Hohenberger, Torsten Hothorn, Dirk Arnold, Ralf-Dieter Hofh einz, Michael Ghadimi, Hendrik A Wolff , Marga Lang-Welzenbach, Hans-Rudolf Raab, Christian Wittekind, Philipp Ströbel, Ludger Staib, Martin Wilhelm, Gerhard G Grabenbauer, Hans Hoff manns, Fritz Lindemann, Anke Schlenska-Lange, Gunnar Folprecht, Rolf Sauer*, Torsten Liersch*, on behalf of the German Rectal Cancer Study Group
Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation
Christian P Probst, MD, Adan Z Becerra, BA, Christopher T Aquina, MD, Mohamedtaki A Tejani, MD, Steven D Wexner, MD, FACS, Julio Garcia-Aguilar, MD, PhD, Feza H Remzi, MD, FACS, David W Dietz, MD, FACS, John RT Monson, MD, FACS, Fergal J Fleming, MD, on behalf of the Consortium for Optimizing the Surgical Treatment of Rectal Cancer (OSTRiCh)
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
K. Bujko*, L. Wyrwicz, A. Rutkowski, M. Malinowska, L. Pietrzak, J. Kryn´ ski, W. Michalski, J. Olędzki, J. Kusnierz, L. Zając, M. Bednarczyk, M. Szczepkowski, W. Tarnowski, E. Kosakowska, J. Zwolinski, M. Winiarek, K. Wisniowska, M. Partycki, K. Bęczkowska, W. Polkowski, R. Stylin´ ski1, R. Wierzbicki, P. Bury, M. Jankiewicz, K. Paprota, M. Lewicka, B. Ciseł, M. Skórzewska, J. Mielko, M. Bębenek, A. Maciejczyk, B. Kapturkiewicz, A. Dybko, Ł. Hajac, A. Wojnar, T. Lesniak, J. Zygulska, D. Jantner, E. Chudyba, W. Zegarski, M. Las-Jankowska, M. Jankowski, L. Kołodziejski, A. Radkowski, U. Zelazowska-Omiotek, B. Czeremszynska, L. Kępka, J. Kolb-Sielecki, Z. Toczko, Z. Fedorowicz, A. Dziki, A. Danek, G. Nawrocki, R. Sopyło, W. Markiewicz, P. Kędzierawski & J. Wydmanski for the Polish Colorectal Study Group
Risk of Metachronous Colon Cancer Following Surgery for Rectal Cancer in Mismatch Repair Gene Mutation Carriers
Aung Ko Win, MBBS, MPH, Susan Parry, MB ChB, FRACP, Bryan Parry, MD, FRACS, Matthew F. Kalady, MD, Finlay A. Macrae, MBBS, MD, FRACP, FRCP, AGAF, Dennis J. Ahnen, MD, AGAF, Graeme P. Young, MBBS, MD, FRACP, FTSE, AGAF, Lara Lipton, PhD, FRACP, Ingrid Winship, MB ChB, MD, FRACP, Alex Boussioutas, MBBS, PhD, FRACP, Joanne P. Young, PhD, Daniel D. Buchanan, PhD, Julie Arnold, RN2, Loı¨c Le Marchand, MD, PhD, Polly A. Newcomb, PhD, Robert W. Haile, DrPH, Noralane M. Lindor, MD, Steven Gallinger, MD, MSc, FRCSC, John L. Hopper, PhD, and Mark A. Jenkins, PhD
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, and L.A. Diaz, Jr.
Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome
Matthew B. Yurgelun, Brian Allen, Rajesh R. Kaldate, Karla R. Bowles, Thaddeus Judkins, Praveen Kaushik, Benjamin B. Roa, Richard J. Wenstrup, Anne-Renee Hartman, and Sapna Syngal
Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal Cancer
Michael I. D’Angelica, MD, Camilo Correa-Gallego, MD, Philip B. Paty, MD, Andrea Cercek, MD, Alexandra N. Gewirtz, BA, Joanne F. Chou, MPH, Marinella Capanu, PhD, T. Peter Kingham, MD, Yuman Fong, MD, Ronald P. DeMatteo, MD, Peter J. Allen, MD, William R. Jarnagin, MD, and Nancy Kemeny, MD
Prognostic Relevance of Palliative Primary Tumor Removal in 37,793 Metastatic Colorectal Cancer Patients: A Population-based, Propensity Score–adjusted Trend Analysis
Ignazio Tarantino, MD, MSc, Rene Warschkow, MD, MSc, Mathias Worni, MD, MHS, Thomas Cerny, MD, Alexis Ulrich, MD, Bruno M. Schmied, MD, MBA, and Ulrich Guller, MD, MHS
Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials
Matthieu Faron, Jean-Pierre Pignon, David Malka, Abderrahmane Bourredjem, Jean-Yves Douillard, Antoine Adenis, Dominique Elias, Olivier Bouche´, Michel Ducreux
Morbidity and Mortality of Aggressive Resection in Patients With Advanced Neuroendocrine Tumors
Jeffrey A. Norton, MD; Maryann Kivlen, MD; Michelle Li, MD; Darren Schneider, MD; Timothy Chuter, MD; Robert T. Jensen, MD
Pancreatic VIPomas: Subject Review and One Institutional Experience
Amir A. Ghaferi & Karen A. Chojnacki & William D. Long & John L. Cameron & Charles J. Yeo
Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections
Letizia Boninsegna, Francesco Panzuto, Stefano Partelli, Paola Capelli, Gianfranco Delle Fave, Rossella Bettini, Paolo Pederzoli, Aldo Scarpa , Massimo Falconi
Surgical Management of Pancreatic Neuroendocrine Tumors
Amareshwar Chiruvella, MD, David A. Kooby, MD
Surgical Resection Provides an Overall Survival Benefit for Patients with Small Pancreatic Neuroendocrine Tumors
Susan M. Sharpe & Haejin In & David J. Winchester & Mark S. Talamonti & Marshall S. Baker
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
Masao Tanaka, Carlos Fernández-del Castillo, Volkan Adsay, Suresh Chari, Massimo Falconi, Jin-Young Jang, Wataru Kimura, Philippe Levy, Martha Bishop Pitman, C. Max Schmidt, Michio Shimizu, Christopher L. Wolfgang, Koji Yamaguchim, Kenji Yamao
A Meta-analysis of the Effect of Prophylactic Central Compartment Neck Dissection on Locoregional Recurrence Rates in Patients with Papillary Thyroid Cancer
Tracy S. Wang, MD, MPH, Kevin Cheung, MSc, MD, Forough Farrokhyar, MPhil, PhD, Sanziana A. Roman, MD, and Julie Ann Sosa, MD, MA
Biologic and Clinical Perspectives on Thyroid Cancer
James A. Fagin, M.D., and Samuel A. Wells, Jr., M.D.
Prognostic Impact of Serum Thyroglobulin Doubling-Time Under Thyrotropin Suppression in Patients with Papillary Thyroid Carcinoma Who Underwent Total Thyroidectomy
Akira Miyauchi, Takumi Kudo, Akihiro Miya, Kaoru Kobayashi, Yasuhiro Ito, Yuuki Takamura, Takuya Higashiyama, Mitsuhiro Fukushima, Minoru Kihara, Hiroyuki Inoue, Chisato Tomoda, Tomonori Yabuta, and Hiroo Masuoka